Navigation Links
Torax Medical Launches Pivotal Clinical Study of New Acid Reflux Treatment

ST. PAUL, Minn., April 3 /PRNewswire/ -- Torax Medical Inc., a medical device company focused on the minimally invasive treatment of gastroesophageal reflux disease (GERD) has commenced a pivotal clinical trial of its LINX(TM) Reflux Management System. The trial, which is being conducted at 15 leading academic and private medical centers in the U.S. and Europe, will evaluate the safety and effectiveness of the LINX System in patients suffering from GERD despite medical therapy.

GERD is caused by a defective lower esophageal sphincter, a ring-like muscular valve that surrounds the esophagus. When defective, it allows abnormal reflux of stomach acids and bile into the esophagus. Approximately 19 million adults in the U.S. suffer on a daily basis from the symptoms of GERD. Medical therapy, such as the daily use of proton pump inhibitors (PPIs), may improve heartburn symptoms but it does not address the mechanically defective sphincter, allowing gastric reflux to continue. Chronic gastric reflux may lead to numerous complications including ulcerations and esophageal cancer. The incidence of esophageal cancer is rising at a faster rate than any other cancer in the U.S.

Robert Ganz, M.D. of Minnesota Gastroenterology and a Principal Investigator in the trial shared these comments, "Many people who suffer from GERD do not get complete relief of symptoms with drug therapy. The LINX System is intriguing because it may provide both symptom relief and correction of the physiologic defect."

The LINX Reflux Management System is intended to restore the normal barrier function in the esophagus for patients who suffer from GERD and is designed to be an outpatient, minimally invasive procedure. The device is implanted laparoscopically, with the patient likely to resume normal activities and diet at discharge. In addition to its therapeutic benefits, Torax Medical anticipates that the LINX System will have the potential to eliminate the burdens associated with lifelong drug therapy and the typical complications associated with conventional surgical repair.

Todd Berg, President and CEO of Torax Medical, considers the LINX System a promising advancement for the treatment of GERD, "We believe the simplest approach to treating GERD is to augment the body's existing sphincter so that it can function normally. Excellent clinical results were achieved in feasibility trials with the LINX System and we expect these positive clinical outcomes to continue in this Pivotal Trial".

To learn more about the study and to determine if you qualify as a candidate, visit or call 1-888-978-8391.

The LINX Reflux Management System is an investigational device and is limited by Federal U.S. law to investigational use only and is not available for sale.

About Torax Medical

Torax Medical Inc. is a privately held medical device company focused on the minimally invasive treatment of gastro-esophageal reflux disease. Its platform technology utilizes magnetic attraction forces to augment the body's sphincter anatomy. For more information, please visit

SOURCE Torax Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
3. Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
4. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
6. Premier Research Expands its Medical Device Operations to the United States
7. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
8. Dermatologists Caution That Severe Cases of Psoriasis Can Be Associated With Other Serious Medical Conditions
9. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
10. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
11. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Post Your Comments:
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... 2016 The vast majority of dialysis patients ... Treatments are usually 3 times a week, with treatment ... travel time, equipment preparation and wait time.  This regimen ... for patients who are elderly and frail.  Many elderly ... rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... D.C. (PRWEB) , ... June 25, 2016 , ... ... discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, ... their work on several important health care topics including advance care planning, healthcare ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):